Who
D. Jeffrey Keyser
Director
Company insider
Files Form 4 as: Director, Lantern Pharma; Chief Operating Officer, ZS Pharma; V.P., Regulatory Affairs, Encysive Pharmaceuticals.
In numbers
- Trades disclosed
- 47
- Buys
- 2
- Sells
- 0
- Bought
- $350K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 11 Dec 2007
- Last trade
- 12 May 2026
- Last filed
- 14 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 May 2026filed 14 May 2026 | LTRN Lantern PharmaBiotechnology | SEC FORM 4 Bought | $100K48,544 at $2.06 | filing |
| 12 May 2026filed 14 May 2026 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code P | —48,544 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code P | —48,544 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | LTRN Lantern PharmaBiotechnology | SEC FORM 4 Bought | $100K48,544 at $2.06 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,844 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,844 at $0.00 | filing |
| 24 Jul 2024filed 26 Jul 2024 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code X | —3,832 at $0.00 | filing |
| 24 Jul 2024filed 26 Jul 2024 | LTRN Lantern PharmaBiotechnology | SEC FORM 4 Code X | $12K3,832 at $3.13 | filing |
| 15 Jul 2024filed 17 Jul 2024 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 4 Nov 2021filed 23 Sep 2025 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,200 at $0.00 | filing |
| 4 Nov 2021filed 23 Sep 2025 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,200 at $0.00 | filing |
| 4 Nov 2021filed 8 Nov 2021 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,200 at $0.00 | filing |
| 15 Jun 2020filed 23 Sep 2025 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code D | —9,135 at $0.00 | filing |
| 15 Jun 2020filed 23 Sep 2025 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,135 at $0.00 | filing |
| 15 Jun 2020filed 15 Jun 2020 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —18,349 | filing |
| 15 Jun 2020filed 15 Jun 2020 | LTRN Lantern Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,135 | filing |
| 15 Jun 2020filed 15 Jun 2020 | LTRN Lantern PharmaBiotechnology | SEC FORM 4 Code C | —31,927 | filing |
| 11 Jun 2020filed 15 Jun 2020 | LTRN Lantern PharmaBiotechnology | SEC FORM 4 Bought | $150K10,000 at $15.00 | filing |
News
Lantern Pharma (NASDAQ:LTRN) Stock Price Up 1.4% – Here's What HappenedLTRN · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name D. Jeffrey Keyser; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.